Spruce Biosciences (SPRB)
NASDAQ:SPRB
Want to see SPRB full AI Analyst Report?
SPRB Stock Chart & Stats
$70.30
--
Market closed
$70.30
--
Day’s Range― - ―
52-Week Range$4.35 - $240.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)988.68K
Market Cap
$154.88M
Enterprise Value$28.01M
Total Cash (Recent Filing)$48.91M
Total Debt (Recent Filing)$736.00K
Price to Earnings (P/E)―
Beta-10.43
Next Earnings
May 13, 2026EPS Estimate
-7.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.73
Shares Outstanding2,702,043
10 Day Avg. Volume2,922,716
30 Day Avg. Volume988,676
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.60K
Enterprise Value/Ebitda-0.79
Forecast
1Y Price Target
$198.25Price Target Upside182.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-36.72
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesExtended clinical data reporting biomarker normalization alongside stabilization of cognitive and adaptive functions and organ size indicate potential meaningful clinical benefit for patients.
Non-dilutive Funding OpportunityEligibility for a Priority Review Voucher and program reauthorization create a material non-dilutive funding option that could improve financial flexibility at approval.
Regulatory PathwayFDA agreement that integrated clinical and natural history data and a cerebrospinal fluid biomarker could support a surrogate endpoint strengthens the case for accelerated approval and reduces regulatory uncertainty.
Bears Say
Funding Gap RiskAnalyst notes that additional funding may be required to support operations through regulatory approval and U.S. market entry, increasing the risk of dilution or further capital raises.
Timeline And Execution RiskRevision to the filing timeline raises the likelihood of needing extra capital and heightens execution risk during the commercial launch process.
Spruce Biosciences News
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $4.35 and its highest was $240.00 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $154.88M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is May 13, 2026 which is in 12 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on Mar 09, 2026. The company reported -$8.73 earnings per share for the quarter, beating the consensus estimate of -$9.158 by $0.428.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -7.93.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 2,702,043 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$8.73 in its last earnings report, beating expectations of -$9.158. Following the earnings report the stock price went up 11.169%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Currently, no hedge funds are holding shares in SPRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spruce Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$198.25 (182.01% Upside)
$198.25 (182.01% Upside)
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
312.60%
12-Months-Change
Fundamentals
Return on Equity
-203.99%
Trailing 12-Months
Asset Growth
17.28%
Trailing 12-Months
Company Description
Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
SPRB Stock 12 Month Forecast
Average Price Target
$198.25
▲(182.01% Upside)
Technical Analysis
Ownership Overview
67.43% Insiders
0.81% Mutual Funds
16.59% Other Institutional Investors
14.42% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---